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ABSTRACT
Cyclin dependent kinases are proline-directed serine/threonine protein kinases 
that are traditionally activated upon association with a regulatory subunit. For most 
CDKs, activation by a cyclin occurs through association and phosphorylation of the 
CDK’s T-loop. CDK5 is unusual because it is not typically activated upon binding with 
a cyclin and does not require T-loop phosphorylation for activation, even though it 
has high amino acid sequence homology with other CDKs. While it was previously 
thought that CDK5 only interacted with p35 or p39 and their cleaved counterparts, 
Recent evidence suggests that CDK5 can interact with certain cylins, amongst other 
proteins, which modulate CDK5 activity levels. This review discusses recent findings 
of molecular interactions that regulate CDK5 activity and CDK5 associated pathways 
that are implicated in various diseases. Also covered herein is the growing body of 
evidence for CDK5 in contributing to the onset and progression of tumorigenesis.
INTRODUCTION
Cyclin dependent kinases are proline-directed 
serine/threonine protein kinases that are traditionally 
activated upon association with a regulatory subunit. 
CDKs are a part of a kinase family that has been 
conserved throughout evolution and can be found in 
species from Saccharomyces cerevisia to humans. In 
humans there are 13 different CDKs (CDK1 - CDK13) 
that are highly expressed in mitotic cells [1]. For most 
CDKs, activation by a cyclin occurs through association 
and phosphorylation of the CDK’s T-loop. Despite having 
high amino acid sequence homology with other CDKs, 
CDK5 is unusual because it is not typically activated 
upon binding with a cyclin and does not require T-loop 
phosphorylation for activation. Additionally, CDK5 
has functions in both terminally differentiated and 
proliferating cells [2]. CDK5 was first identified in 1992 
by multiple groups and was given a different name by 
each, including tau kinase II [3], neuronal Cdc2 like 
kinase [4], brain proline-directed kinase [5], PSSALRE 
[6], and CDK5 [7]. An isoform of CDK5, termed either 
CDK5-SV or CDK5-V1, was recently discovered [8, 9]. 
One study reported that this splice variant lacks 32 amino 
acids encoded by exon 7 [8], while another study stated 
the missing 32 amino acids are encoded by exon 6 [9]. 
Although these two groups reported conflicting data, it has 
been suggested that the identified isoforms are in fact the 
same protein and the variances in their data are due to 
different methodologies [10]. 
CDK5 can be mapped to chromosome 7q36 and its 
expression is upregulated by the transcription factors Fos 
and CREB through the MEK/ERK pathway and by δFosB 
[11, 12]. CDK5 plays a vital role in the central nervous 
system but has functions in other cell types. Outside of the 
nervous system, active CDK5 has been found in pancreatic 
β cells [13], corneal epithelial cells [14] and monocytes 
[15] amongst various other cell types [10, 16]. In the 
nervous system, CDK5 is involved in neuron migration, 
neurite outgrowth and support, and synaptogenesis. 
CDK5’s function in cells other than neurons includes 
the induction of cell motility, apoptosis, and cell cycle 
progression as well as functions involved with the immune 
system, lymphatic system, vascularization, and insulin 
secretion. A summary of CDK5 functions as discussed 
herein can be found in Table I. CDK5 has recently been 
implicated in diseases, including the development and 
progression of cancer and neurodegenerative diseases. 
For this reason, the regulation of CDK5 activity is now 
emerging as a candidate therapeutic target. 
Review
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CDK5 ACTIVATORS AND REGULATORS
Unlike other CDKs, CDK5 is not primarily 
activated by cyclins. Instead it is through specific binding 
with the proteins p35 or p39, or their respective cleaved 
counterparts p25 and p29, that CDK5 becomes active 
[1, 17, 18]. It was found that p35 knockout mice have 
defective cortical lamination and adults suffered from 
sporadic lethality and seizures [19], which is a less severe 
phenotype than that exhibited by Cdk5 knockout mice 
[20]. p39-/- mice did not display any obvious abnormalities, 
however p35/p39 compound knockout mice displayed 
a phenotype identical to that of the Cdk5-/- mice [21], 
suggesting that while p39 may not play a pivotal role in 
Cdk5 activation, it becomes necessary for nervous system 
development in the absence of p35.
p35 has a myristolation sequence that localizes 
it to phospholipid membranes [22]. Active CDK5 
can phosphorylate p35 at Ser8 and Thr138. In the 
brain, phosphorylation of S8 is constant throughout 
development, but phosphorylation of T138 is found more 
abundantly in fetal brain tissue [23]. The phosphorylation 
at S8 leads to a more diffuse localization throughout the 
cytoplasm. This could be due to increased p35 mobility 
on membranes due to an altered interaction between the 
protein and phospholipids that constitute cell membranes 
[24]. p35 phosphorylation at T138 prevents its cleavage to 
p25 by calpain [23]. Because CDK5 has various regulatory 
functions in neuron development and migration, it is likely 
that the phosphorylation of p35 at T138 protects against 
aberrant CDK5 activation through formation of p25 in 
the fetal stage of brain development when CDK5 activity 
is also high [1]. Additionally, in vitro, under conditions 
of oxidative stress, p35 has been found conjugated to 
SUMO2 at Lys246 and Lys290, which led to increased 
p35/CDK5 activity [25].
Table I: Cyclin dependent kinase 5’s functions in various biological systems and cellular processes.
Biological system/ process CDK5 function Mechanism
Central nervous system
Support growth cones
CDK5 phosphorylates CRMP2A at Ser27 during 
semaphorin3A stimulation. CDK5 also phosphorylates 
neurofilament heavy chain to promote neurofilament 
assembly [33-35]
Growth cone collapse
CDK5 associates with alpha2-chimerin and 
phosphorylates CRMP2 at Ser522. CRMP2 further 
phosphorylated and inactivated by GSK3beta [37]
Immune system Increased IFNγ-induced PD-L1 expression
CDK5 expression decreases the expression of PD-L1 
transcriptional repressors (IRF2 and IRF2BP) [55]
Insulin secretion Reduction of insulin secretion CDK5 phosphorylates L-VDCC and prevents exocytosis of insulin [13]
Vascular Promotes angiogenesis CDK5 expression increases abundance of HIF-1α [53]
Lymphatic Lymphatic valve formation CDK5 phosphorylates Foxc2, which regulates the expression of connexin 37 [59]
Cell Cycle
Increased expression of cyclins and 
other CDK's Rb is a downstream target of CDK5's activity [50]
Reduction of CDK5 activity Cyclin D1 and cyclin E can bind CDK5 to prevent CDK5's activation [39, 40]
Cancer Progression
Cell proliferation Reduction of p25 expression or CDK5 expression can prevent proliferation [50]
Cell migration/ metastasis
CDK5 activity leads to caldesmon phosphorylation and 
actin polymerization. CDK5 enhances pro-migratory 
P13K/AKT signaling [61, 62]
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Table II: Previous and ongoing cancer clinical trials using cyclin dependent kinase inhibitors [64, 65]
Treatment Major Targets Disease(s) Clinical trial identifier 
Terameprocol CDK1 Phase I: Leukemia, refractory solid tumors, lymphoma, glioma
NCT00664677, 
NCT00664586, 
NCT00404248
PHA-793887 CDK1, CDK2, CDK4 Phase I: Solid tumors NCT00996255
Flavopiridol CDK1, CDK2, CDK4, CDK7, CDK9
Phase I-II: Various cancer including leukemia, multiple 
myeloma, lymphoma, sarcoma, and solid tumors (alone 
and in combination with other cytotoxic drugs)
NCT02520011, 
NCT00112723, 
NCT00005974, 
NCT00098579, 
NCT00007917,
NCT00324480
BAY1000394 CDK1, CDK2, CDK4, CDK9 Phase I: solid tumors NCT01188252
Dinaciclib CDK1, CDK2, CDK5, CDK9
Phase I-II: Advanced malignancies and relapsed 
multiple myeloma (alone and in combination with other 
cytotoxic drugs)
NCT01783171, 
NCT01624441,
NCT01096342,
NCT02684617,
NCT01434316,
NCT00871663,
NCT01624441
P276-00 CDK1, CDK4, CDK9 Phase I-II: Multiple myeloma, mantle cell lymphoma, head and neck cancers, cyclin D1-positive melanoma
NCT00882063,
NCT00848050,
NCT00824343,
NCT00899054,
NCT00835419
AT7519 CDK2, CDK4, CDK5, CDK9
Phase I: Advanced or metastatic solid tumors, 
lymphoma
NCT02503709,
NCT01652144,
NCT01627054
R-roscovitine CDK2, CDK5 Phase I-II: Advanced solid tumors, non-small cell lung cancer
NCT00999401,
NCT00372073
SNS-032 CDK2, CDK7, CDK9 Phase I: B-lymphoid malignancies and advanced solid tumors NCT00446342
P1446A-05 CDK4 Phase I: Advanced refractory solid tumors and hematological tumors
NCT00840190
NCT00772876
PD 0332991 CDK4, CDK6
Phase I: Advanced cancers, mantle cell lymphoma
Phase II: Multiple myeloma, advanced breast cancer, 
non-small cell lung cancer, ovarian cancer
NCT01522989,
NCT00141297,
NCT02008734,
NCT02101034,
NCT01976169,
NCT01907607,
NCT01356628,
NCT01291017,
NCT01536743
LY2835219 CDK4, CDK6 Phase I-II: Metastatic breast cancer, non small cell lung cancer
NCT02102490,
NCT02246621,
NCT02441946,
NCT02450539,
NCT02079636,
NCT02779751
NCT02152631,
NCT02675231
This is representative rather than a comprehensive list of past and present clinical trials in the field.
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As previously mentioned, the CDK5 activator p25 is 
formed through cleavage of p35 by calpain. This produces 
both the p25 product as well as a p10 product. Cleavage 
of p35 occurs under stress conditions such as amyloidβ 
presence, excitotoxicity, or oxidative stress [22, 26]. This 
cleavage allows p25 to localize to nuclear and perinuclear 
regions by removing the p10 myristolation sequence 
[22]. Compared with p35, p25 has a longer half-life, and 
therefore prolongs the activation period of CDK5, leading 
to increased phosphorylation of CDK5’s target proteins 
[22, 27]. 
The functions of CDK5 activators p39 and p29 
largely overlap with those of p35 and p25, respectively, 
however their expression throughout brain regions vary. 
p39 and p29 are mainly expressed in postnatal cerebral 
cortex and the hindbrain while p35 and p25 are largely 
expressed in the cerebral cortex of developing brains 
[27]. The localization of p39 to membranes is similar to 
that of p35 due to its conserved myristolation sequence 
[22]. Likewise, p39 also shows a more diffuse localization 
upon phosphorylation of Ser8 by CDK5 [24]. p39 can 
be phosphorylated by CDK5 at Ser173, a site equivalent 
to T138 in p35, and Thr84, however the effect of these 
phosphorylations on controlling protein stability have not 
yet been explored [1, 24].
In addition to p35 and p39, cyclin I has also been 
shown to activate CDK5. Cyclin I-CDK5 binding targets 
CDK5 to the nucleus [28] and increases levels of anti-
apoptotic proteins Bcl2 and Bcl2l1 via the MEK/ERK 
pathway [29]. This upregulation of Bcl2 and Bcl211 is 
observed only through cyclin I activation of CDK5, not 
activation via p35 [29, 30]. CDK5 has been found to bind 
cyclin D1 and cyclin D3 in human fibroblasts, however 
this interaction had no influence on the activation and 
kinase activity of CDK5 [7, 31].
While CDK5 is only activated by p35/p25, p39/p29, 
or cyclin I, the activity of CDK5 can be modulated by 
a variety of other proteins, as depicted in Figure 1. For 
instance, cyclin D1 can attenuate CDK5 kinase activity 
by competing with p35 for binding with CDK5, thereby 
forming an inactive complex of cyclin D1 and CDK5 (Fig. 
1). CDK5 and cyclin D1 can be found in the rat cerebellum 
during the first 24 days of postnatal development, albeit at 
varying abundances. CDK5 abundance increased while 
cyclin D1 decreased from day 9 on to adulthood [32]. In 
post-mitotic neurons, cyclin D1/CDK5 association was 
found to lead to cell cycle related neuronal apoptosis 
through sustained MEK/ERK signaling [33]. 
Cyclin E can directly interact with Cdk5 to reduce 
its activity. Cyclin E was found to sequester mouse 
Figure 1: Simplified schematic of the regulation of CDK5 activity.
Oncotarget17377www.impactjournals.com/oncotarget
Cdk5 away from other protein activators along with 
p27KIP1. The formation of this complex, and consequent 
attenuation of Cdk5 activity was found to promote 
synaptic plasticity, memory formation, and dendritic 
growth, as cyclin E-/- mice, that had increased Cdk5 
activity, were deficient in these processes [34]. While 
this result may seem counterintuitive due to active 
CDK5’s function with supporting neurite outgrowths, this 
observation could be explained by an overabundance of 
active CDK5 detrimentally effecting neurite outgrowth 
and subsequently synaptic plasticity. This theory would 
be consistent with findings that CDK5 expression levels 
are increased in certain neurodegenerative diseases, and 
that it is the aberrant CDK5 activity that leads to neurite 
collapse and death [35-37]. 
Glutathione-S-transferase (GSTP1) is another 
regulator of CDK5 activity that functions by competing 
with p35 for CDK5 binding. GSTP1 also reduces aberrant 
CDK5 activity by scavenging for molecules associated 
with oxidative stress and thereby decreasing the likelihood 
of p35/p39 cleavage to p25/p29 [38] (Figure 1). 
TP53 induced glycolysis regulatory phosphatase 
(TIGAR) has been shown to upregulate CDK5 expression 
levels in the presence of induced DNA damage (Figure 1). 
Knockdown of TIGAR led to decreased CDK5 expression, 
decreased phosphorylated ATM, and consequently 
increased levels of induced DNA damage. This suggests 
that DNA damage repair is mediated via TIGAR activation 
of the CDK5-ATM pathway [39].
CDK5 IN CELL CYCLE AND OTHER 
PATHWAYS
Previously, CDK5 was thought to function in 
a cell cycle independent manner; however, recently 
the retinoblastoma protein (Rb) was discovered as a 
downstream target of CDK5. Expression of CDK5 
leads to the phosphorylation of Rb, ultimately leading 
to the expression of cyclins and other cdks [40]. The 
protein kinase CK1 is phosphorylated by CDK5, and is 
involved in a wide array of signaling pathways including 
cell cycle, DNA repair, and apoptosis [41]. When CDK5 
phosphorylates CK1, its kinase activity is subsequently 
reduced [42]. The functional affect of CDK5-mediated 
phosphorylation of CK1 on cell cycle, DNA repair, or 
apoptosis has yet to be explored. 
In pancreatic β cells, CDK5 activity reduces insulin 
secretion in response to glucose abundance (Figure 2). 
This was demonstrated using CDK5 inhibitors, as well 
Figure 2: Simplified schematic of CDK5 activities.
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as inhibition of CDK5’s activator p35. When CDK5 is 
active, it phosphorylates the L-type voltage-dependent 
Ca+2 channel (L-VDCC) at Ser783, which prevents the 
association of L-VDCC with syntaxin and SNAP-25, 
thereby preventing exocytosis of insulin from the cell [13].
Within the immune system, CDK5 has been 
implicated in IFNγ-induced programmed death ligand 
1 (PD-L1) upregulation, which allows certain cells 
to evade detection by the immune system. Decreased 
CDK5 expression led to increased expression of the 
PD-L1 transcriptional repressors IRF2 and IRF2BP and 
consequent decreased PD-L1 expression (Figure 2) [43]. 
PD-L1 is a ligand that binds with PD-1, which is found 
on various immune cells. The binding of PD-L1 and 
PD-1 decreases an immune response by inhibiting T-cell 
activation and cytokine production. In normal tissues this 
is vital for maintaining homeostasis [44]. However tumor 
cells can also express PD-L1, which allows them to avoid 
detection and elimination by T-cells [45, 46].
CDK5 promotes the formation of lymphatic vessels. 
CDK5 phosphorylates Foxc2, a protein that regulates the 
expression of connexin 37, which is critical for lymphatic 
valve formation (Figure 2). Moreover, knockout of CDK5 
in the endothelium leads to lymphedema formation and 
embryonic lethality in mice [47].
CDK5 has previously been implicated in the 
migration of neurons. CDK5 knockout mice have 
abnormal cortical lamination, and more than 60% of 
CDK5-/- mice died in utero [20]. Various studies have 
since implicated CDK5 in cell migration as it governs 
cancer metastasis. In prostate cancer cells, inhibition of 
CDK5 by the drug roscovitine prevented cell migration. 
The roscovitine treated cells did not project lamellopodia, 
and had reduced tubulin structures compared to untreated 
cells. This suggests that CDK5 inhibition prevented the 
establishment of cell polarity required for movement [48]. 
Additionally, knockdown of CDK5 in melanoma cell 
lines decreased cell motility and cell spreading in vitro, 
and decreased formation of lung and liver metastases in 
vivo in a mouse model of human melanoma. The decrease 
in CDK5 expression led to decreased phosphorylation 
of caldesmon, which decreased its binding affinity with 
actin and calmodulin (Figure 2) [49]. Another mechanism 
by which CDK5 may promote cell migration is by 
enhancing pro-migratory P13K/AKT signaling. CDK5 
phosphorylates the Gα –interacting vesicle associated 
protein (GIV), which promotes GIV interaction with Gαi, 
thereby enhancing P13K/AKT signaling (Figure 2) [50]. 
Together, these studies demonstrate the importance of 
CDK5 in cell motility, a naturally occurring and necessary 
process. However, CDK5 mediated movement could also 
be an underlying driver of cancer metastasis and could be 
targeted in treatments to halt cancer metastasis.
CYTOSKELETAL ORGANIZATION
An important function of CDK5, especially in 
neurons, is the organization of the cytoskeleton and 
support of cellular outgrowths (Figure 2). Expression of 
p35 or p39 in vitro stimulates neurite outgrowths, and a 
dominant negative mutant of CDK5 was found to abolish 
the formation of these outgrowths [51]. CDK5 supports 
axon and neurite outgrowth is through phosphorylation of 
the neurofilament heavy chain, resulting in the assembly 
of neurofilaments [52]. 
CDK5 has been shown to both prevent and promote 
growth cone collapse under different circumstances. 
CDK5 phosphorylates the protein CRMP2A at Ser27, 
which can be stabilized by Pin1 to support the growth of 
growth cones in the presence of semaphorin3A stimulation 
[53, 54]. Additionally, CDK5 can promote axonal growth 
through indirect activation of CRMP2 by phosphorylating 
the protein Axin. Phosphorylated Axin inhibits GSK3β 
activity, leading to an increase in active, unphosphorylated 
CRMP2 [55] (Figure 2). 
Conversely, CDK5 promotes the collapse of growth 
cones through association with CRMP2 and α2-chimerin, 
an adaptor protein between CRMP2 and CDK5-p35. This 
association of CRMP2, α2-chimerin, and CDK5-p35 
promotes the phosphorylation of CRMP2 at Ser522 by 
CDK5. In turn, this allows for CRMP2 to associate with 
and be phosphorylated at T514 by GSK3β, resulting in 
CRMP2 inactivation, microtubule disassembly, and 
ultimately growth cone collapse [56]. In this manner, 
CDK5 activity can both prevent and promote collapse of 
growth cones.
CDK5 can also reduce cellular outgrowth 
by regulating cytoskeletal organization through 
phosphorylation of p35 at T138, which prevents the 
polymerization of microtubules. This phosphorylation at 
T138 is found primarily in fetal brain tissues as opposed 
to adult brain [23].
ROLE OF CDK5 IN NEUROLOGICAL 
DISEASE
Due to the many roles of CDK5 in the development 
of the nervous system, as well as the effects of cellular 
stress on CDK5 activation, CDK5 has been implicated 
in the progression of various neurological diseases and 
as a potential therapeutic target in disease treatment. For 
instance, while CDK5 normally phosphorylates collapsin 
response mediator protein 2 (CRMP2) to stimulate 
axon growth, it was found that hyperphosphorylation of 
CRMP2, as well as Tau, were implicated in the generation 
of neurofibrillary tangles characteristic of Alzheimer’s 
disease [53]. Cell stress, including the presence of 
amyloid beta, is known to aberrantly activate CDK5 due 
to the formation of p25, which has been shown to cause 
the hyperphosphorylation of Tau, leading to atypical cell 
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cycling, synaptotoxicity, and neuronal apoptosis [57]. 
Additionally, increased CDK5 activity caused by the 
sumoylation of p35 under oxidative stress, also contributes 
to neurodegeneration [25].
While CDK5 overexpression and aberrant activation 
are associated with neurodegenerative diseases, a loss 
or reduction in CDK5 activity is implicated in certain 
intellectual disabilities and neurodevelopmental disorders. 
Decreased CDK5 activity has been associated with 
intellectual disability in NF1 microdeletion syndrome 
patients [58] and schizophrenia [59]. Additionally, 
transgenic mice with decreased Cdk5 activity exhibited 
spontaneous seizures [60] as well as behaviors similar to 
ADHD [61].
CDK5 EXPRESSION IN CANCER 
Elevated levels of CDK5 have been found in 
various mouse tumors and human malignant tumors 
[40] [53, 62-65]. The mechanisms involve effects on 
angiogenesis, cell proliferation and the immune system. 
As noted above, CDK5 enhances pRb phosphorylation 
and thereby cell-cycle progression [40]. Furthermore, CK1 
is phosphorylated by CDK5, which in turn governs cell 
cycle, DNA repair, and apoptosis [41]. Increased levels 
of CDK5 target proteins are being considered as possible 
biomarkers of specific cancers. For example, an increase 
in CRMP2 phosphorylation could be a potential biomarker 
for certain lung cancers, as phosphorylated CRMP2 was 
found in the nuclei of biopsied lung cancer cells, but not 
cells in the surrounding epithelium [53]. 
In a transgenic mouse model of sporadic medullary 
thyroid carcinoma (MTC), p25 overexpression led to 
the development of bilateral malignant thyroid tumors, 
and was fatal after 30 weeks. However, arresting p25 
expression at 5, 11, or 16 weeks led to 100 percent survival 
in all mice analyzed after 30 weeks. Similar results were 
discovered in vitro, in which reducing p25 expression or 
knocking down Cdk5 expression prevented further cell 
proliferation. This suggests that it is the aberrant activation 
of Cdk5 by p25 that leads to the progression of sporadic 
MTC [40]. 
CDK5 expression in medulloblastoma allows tumor 
cells to evade detection by T-cells in vivo. Conversely, 
decreased CDK5 expression enhanced the recruitment of 
CD4+ T-cells to the tumor site in mice, and increased the 
tumor-free survival rate of the mice. CDK5 regulates the 
evasion of tumors from the immune system by decreasing 
expression of transcriptional repressors of PD-L1 
expression, thus increasing the abundance of PD-L1 [45].
Inhibiting CDK5 activity in hepatocellular 
carcinoma (HCC) cells prevented angiogenesis in vivo 
by decreasing the abundance of HIF-1α. Because HCC is 
a highly vascularized tumor type, inhibiting CDK5 and 
therefore angiogenesis, could prove a promising treatment 
for this tumor subtype and other highly vascularized 
tumors [64]. 
CDK5 AS A TARGET FOR DISEASE 
TREATMENT
Due to the biological and clinically relevant 
importance of CDK5’s function in multiple cell types, 
CDK5 presents an attractive therapeutic target for 
treating a variety of conditions such as diabetes, cancer, 
and neurodegeneration. Additionally, the upregulation 
of CDK5 associated with various cancers and 
neurodegenerative diseases further implicates its role in 
the development and progression of disease. Recently, 
tamoxifen (TMX), a drug currently used in breast cancer 
treatment, was found to decrease CDK5 activation by 
competitively binding with p35 and p25, and preventing 
their activation of CDK5. While the TMX inhibition of 
CDK5 activity could contribute to the anti-tumor effects of 
the drug, TMX treatment was also found to decrease Tau 
phosphorylation, suggesting a use for tamoxifen in treating 
Alzheimer’s disease [66]. However, because of the broad 
functions of CDK5 in different cell and tissue types and 
the pan CDK inhibitory effect on other family members, 
the off target affects of a CDK5 inhibitory drug may create 
undesirable side effects. Nonetheless, CDK inhibitors 
are an intriguing clinical therapy for the treatment of 
various cancers. A list of current cyclin-dependent kinase 
inhibitors, including inhibitors of CDK5, and their 
associated clinical trials for the treatment of cancer can be 
seen in Table II.
One of the most well studied CDK inhibitors 
being used in cancer clinical trials is flavopiridol, a drug 
developed by Tolero pharmaceuticals under the name 
Alvocidib. Flavopiridol was found to competivively bind 
to the ATP-binding pocket of CDK1, CDK2, CDK4, and 
CDK9, consequently inducing apoptosis in both dividing 
and quiescent cells. Early clinical trials with flavopiridol 
as a monotherapy proved ineffective in that there was a 
narrow window between no clinical response and severe, 
lethal tumor lysis. Ongoing trials involve combination 
therapies with other novel chemotherapy agents to 
overcome the limitations of flavorpiridol [67]. 
Another relatively well studied CDK inhibitor, 
Dinaciclib, was found to be more efficacious than 
flavopiridol, with IC50 values in the low nanomolar range 
(1-4 nM – in various models flavopiridol’s IC50 values 
range from 50-350 nM) [67, 68]. Dinaciclib selectively 
inhibits CDK1, CDK2, CDK5, and CDK9 [67]. 
Preclinical studies and early clinical trials demonstrated 
the cytotoxicity of Dinaciclib in solid tumors and chronic 
lymphocytic leukemia, while not affecting T-cell function 
or number [69].
Roscovitine, marketed under the name Seliciclib, is 
an inhibitor of CDK5 and CDK2. Many of the clinical 
trials for Seliciclib were intiated determine dose-limiting 
toxicities of the drug alone or in combination with other 
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chemotherapeutics. While roscovitine is used widely 
experimentally to inhibit CDK5 activity, it is not being 
intensively examined as a clinical cancer therapeutic [67]. 
To potentially reduce broad undesirable off 
target effects of pan-CDK inhibitors, CDK5 inhibitory 
peptide (CIP) has been studied as a potential therapeutic 
for neurodegeneration. CIP specifically targets the 
hyperactivated state of CDK5 as mediated by p25/p29, 
while allowing normal activation of CDK5 by p35/p39. 
CDK5 inhibitory peptide (CIP) was found to inhibit 
the hyperactivation of CDK5 by p25 overexpression in 
vivo, which reduced neurodegeneration and improved 
cognitive function of transgenic mice, without affecting 
neurodevelopment [70]. In the future, CIP could possibly 
be adapted to treat certain cancers caused by aberrant 
CDK5 activation.
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